AR023824A1 - Terapia de hiv combinacion de antagonista ccr5-interferon alfa pegilado. - Google Patents
Terapia de hiv combinacion de antagonista ccr5-interferon alfa pegilado.Info
- Publication number
- AR023824A1 AR023824A1 ARP000102097A ARP000102097A AR023824A1 AR 023824 A1 AR023824 A1 AR 023824A1 AR P000102097 A ARP000102097 A AR P000102097A AR P000102097 A ARP000102097 A AR P000102097A AR 023824 A1 AR023824 A1 AR 023824A1
- Authority
- AR
- Argentina
- Prior art keywords
- ccr5
- antagonist
- pegilado
- hiv
- interferon alfa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Se describe el uso de un interferon-alfa pegilado, y el antagonista CCR5, adicionalmente en asociacion con por lo menos uno de ribavirina, IL-2, IL-12,pentafusida sola o en combinacion con una terapia de droga anti HIV-1, por ejemplo HAART, para la preparacion de un medicamento para el tratamiento deinfecciones de HIV-1 así como también coinfecciones de HIV-1 y HCV en pacientes adultos y pediátricos que no han sido sometidos a tratamiento, asícomo también pacientes adultos y pediátricos que hanexperimentado tratamiento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30489799A | 1999-05-04 | 1999-05-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR023824A1 true AR023824A1 (es) | 2002-09-04 |
Family
ID=23178462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000102097A AR023824A1 (es) | 1999-05-04 | 2000-05-02 | Terapia de hiv combinacion de antagonista ccr5-interferon alfa pegilado. |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1175224B1 (es) |
JP (1) | JP2002543144A (es) |
CN (1) | CN1349408A (es) |
AR (1) | AR023824A1 (es) |
AT (1) | ATE289516T1 (es) |
AU (1) | AU776541B2 (es) |
BR (1) | BR0010593A (es) |
CA (1) | CA2365900A1 (es) |
DE (1) | DE60018273T2 (es) |
ES (1) | ES2238277T3 (es) |
HK (1) | HK1039278B (es) |
HU (1) | HUP0202734A3 (es) |
MX (1) | MXPA01011116A (es) |
MY (1) | MY127670A (es) |
NO (1) | NO328679B1 (es) |
NZ (1) | NZ514519A (es) |
PE (1) | PE20010283A1 (es) |
PT (1) | PT1175224E (es) |
TW (1) | TWI289454B (es) |
WO (1) | WO2000066141A2 (es) |
ZA (1) | ZA200108870B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050065319A1 (en) * | 2000-12-19 | 2005-03-24 | Baroudy Bahige M. | Combination method for treating viral infections |
TWI344955B (en) | 2003-03-14 | 2011-07-11 | Ono Pharmaceutical Co | Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient |
US7498323B2 (en) | 2003-04-18 | 2009-03-03 | Ono Pharmaceuticals Co., Ltd. | Spiro-piperidine compounds and medicinal use thereof |
JPWO2004092136A1 (ja) * | 2003-04-18 | 2006-07-06 | 小野薬品工業株式会社 | 含窒素複素環化合物およびその用途 |
DE602005002673T2 (de) | 2004-04-29 | 2008-07-24 | F. Hoffmann-La Roche Ag | Nukleotidsequenzvariation im Gen NS5A als Marker |
PE20060598A1 (es) | 2004-09-13 | 2006-08-21 | Ono Pharmaceutical Co | Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5 |
BRPI0609251A2 (pt) * | 2005-02-23 | 2010-03-09 | Schering Corp | derivados de piperidinil piperazina úteis como inibidores de receptores de quimiocinas |
EP1889622A4 (en) | 2005-05-31 | 2009-12-23 | Ono Pharmaceutical Co | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF |
WO2007049771A1 (ja) | 2005-10-28 | 2007-05-03 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
ES2407115T3 (es) | 2005-11-18 | 2013-06-11 | Ono Pharmaceutical Co., Ltd. | Compuesto que contiene un grupo básico y uso del mismo |
EP1995246A4 (en) | 2006-03-10 | 2010-11-17 | Ono Pharmaceutical Co | NITROGENATED HETEROCYCLIC DERIVATIVE AND MEDICAMENT WITH DERIVATIVE ACTIVE SUBSTANCE |
JP5257068B2 (ja) | 2006-05-16 | 2013-08-07 | 小野薬品工業株式会社 | 保護されていてもよい酸性基を含有する化合物およびその用途 |
US20090325992A1 (en) | 2006-07-31 | 2009-12-31 | Ono Pharmaceutical Co., Ltd. | Compound having cyclic group bound thereto through spiro binding and use thereof |
WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
US20140271680A1 (en) | 2011-08-12 | 2014-09-18 | Universite Paris-Est Creteil Val De Marne | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
CN106831541B (zh) | 2011-11-18 | 2019-09-06 | 赫普泰雅治疗有限公司 | 毒蕈碱性m1受体激动剂 |
EP3091990B1 (en) | 2014-01-08 | 2021-05-12 | Mirror Biologics, Inc. | Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome |
GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
JP2000507917A (ja) * | 1995-11-02 | 2000-06-27 | シェーリング コーポレイション | 持続的低用量サイトカイン注入治療 |
US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
GB9609932D0 (en) * | 1996-05-13 | 1996-07-17 | Hoffmann La Roche | Use of IL-12 and IFN alpha for the treatment of infectious diseases |
AU5522498A (en) * | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
AR013669A1 (es) * | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
-
2000
- 2000-05-01 AU AU46815/00A patent/AU776541B2/en not_active Ceased
- 2000-05-01 JP JP2000615025A patent/JP2002543144A/ja not_active Ceased
- 2000-05-01 EP EP00928604A patent/EP1175224B1/en not_active Expired - Lifetime
- 2000-05-01 AT AT00928604T patent/ATE289516T1/de not_active IP Right Cessation
- 2000-05-01 WO PCT/US2000/011634 patent/WO2000066141A2/en active IP Right Grant
- 2000-05-01 MX MXPA01011116A patent/MXPA01011116A/es active IP Right Grant
- 2000-05-01 HU HU0202734A patent/HUP0202734A3/hu unknown
- 2000-05-01 DE DE60018273T patent/DE60018273T2/de not_active Expired - Lifetime
- 2000-05-01 NZ NZ514519A patent/NZ514519A/en not_active IP Right Cessation
- 2000-05-01 BR BR0010593-7A patent/BR0010593A/pt not_active Application Discontinuation
- 2000-05-01 CA CA002365900A patent/CA2365900A1/en not_active Abandoned
- 2000-05-01 PT PT00928604T patent/PT1175224E/pt unknown
- 2000-05-01 ES ES00928604T patent/ES2238277T3/es not_active Expired - Lifetime
- 2000-05-01 CN CN00807116A patent/CN1349408A/zh active Pending
- 2000-05-02 TW TW089108323A patent/TWI289454B/zh not_active IP Right Cessation
- 2000-05-02 AR ARP000102097A patent/AR023824A1/es unknown
- 2000-05-02 MY MYPI20001893A patent/MY127670A/en unknown
- 2000-05-02 PE PE2000000408A patent/PE20010283A1/es not_active Application Discontinuation
-
2001
- 2001-10-26 ZA ZA200108870A patent/ZA200108870B/xx unknown
- 2001-11-02 NO NO20015367A patent/NO328679B1/no not_active IP Right Cessation
-
2002
- 2002-02-02 HK HK02100826.8A patent/HK1039278B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2238277T3 (es) | 2005-09-01 |
WO2000066141A3 (en) | 2001-02-08 |
HK1039278B (zh) | 2005-06-30 |
NO20015367D0 (no) | 2001-11-02 |
AU776541B2 (en) | 2004-09-16 |
EP1175224B1 (en) | 2005-02-23 |
NO328679B1 (no) | 2010-04-26 |
CA2365900A1 (en) | 2000-11-09 |
JP2002543144A (ja) | 2002-12-17 |
HK1039278A1 (en) | 2002-04-19 |
HUP0202734A2 (hu) | 2002-12-28 |
MXPA01011116A (es) | 2002-06-04 |
MY127670A (en) | 2006-12-29 |
BR0010593A (pt) | 2002-02-13 |
ATE289516T1 (de) | 2005-03-15 |
AU4681500A (en) | 2000-11-17 |
TWI289454B (en) | 2007-11-11 |
DE60018273T2 (de) | 2005-08-18 |
DE60018273D1 (de) | 2005-03-31 |
ZA200108870B (en) | 2003-03-26 |
EP1175224A2 (en) | 2002-01-30 |
WO2000066141A2 (en) | 2000-11-09 |
NO20015367L (no) | 2002-01-03 |
HUP0202734A3 (en) | 2003-11-28 |
NZ514519A (en) | 2003-07-25 |
PE20010283A1 (es) | 2001-03-16 |
PT1175224E (pt) | 2005-07-29 |
CN1349408A (zh) | 2002-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR023824A1 (es) | Terapia de hiv combinacion de antagonista ccr5-interferon alfa pegilado. | |
PE119199A1 (es) | Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica | |
CO5241354A1 (es) | Terapia de combinacio para vhc | |
AR019551A1 (es) | Uso de la ribavirina en combinacion con el interferon alfa para la fabricacion de un medicamento para la terapia de combinacion para erradicar hcv-rna detectable en pacientes no afectados a tratamiento antiviral que tienen infeccion de hepatitis c cronica | |
ES2186714T3 (es) | Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado. | |
AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
BR0114636A (pt) | Terapia combinada para hcv de interferon-alfa peguilado/ribavirina | |
EP2356990A3 (en) | Liposome treatment of viral infections | |
PT1242119E (pt) | Combinacoes para o tratamento de infeccoes por virus adn incluindo um diuretico de ansa e um glicosido cardiotonico | |
BR0108997A (pt) | Terapia imune adjuvante para hiv | |
PE20001386A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa | |
AR022250A1 (es) | Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b. | |
CO5160259A1 (es) | Interferon alfa pegilado en la terapia contra el hiv | |
BR9915644A (pt) | Uso de compostos de 17-cetoesteróides e seus derivados, metabolitos e precursores no tratamento de vìrus de hepatite c e outros togavìrus | |
AR039915A1 (es) | Tratamiento de la hepatitis c en la poblacion asiatica | |
ECSP003462A (es) | Terapia de hiv de combinacion de antagonista ccr5 - interferon alfa pegilado (caso ino1024k) | |
BRPI0409711A (pt) | tratamento ou prevenção de infecções respiratórias virais com peptìdeos da alfa timosina | |
WO2004033479A3 (en) | Retroyclins: antiviral and antimicrobial peptides | |
EP1240899A3 (en) | Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections | |
KR950702838A (ko) | 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4) | |
ECSP003373A (es) | Terapia contra el hiv | |
BR0008269A (pt) | Uso de uma preparação de m. vaccae, e, método para tratamento de infecção viral crÈnica, excluindo infecção por hiv | |
James | Ribavirin approved for hepatitis C combination treatment | |
Baker | Advantages of HIV treatment with Hydrea (Hydroxyurea) | |
Scheibel | Five-drug or six-drug antiretroviral therapy--conversation with Steven Scheibel, MD Interview by John S. James |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |